Yue Yang

Yue Yang

Auto-generated profile, based on publicly available information

Yue Yang

Shanghai United Imaging Microelectronics Technology Co., Ltd., China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2020 in Journal of Medical Internet Research
Verified
Journal Article
Open access
MGMengchun Gong
Mengchun Gong
LLLi Liu
Li Liu
XSXin Sun
Xin Sun
YYYue Yang
Yue Yang
SWShuang Wang
Shuang Wang
HZHong Zhu
Hong Zhu
Background: Coronavirus disease (COVID-19) has been an unprecedented challenge to the global health care system. Tools that can improve the focus of surveillance efforts and clinical decision support are of paramount importance. Objective: The aim of this study was to illustrate how new medical informatics technologies may enable effective control of the pandemic through the development and successful 72-hour deployment of the Honghu Hybrid System (HHS) for COVID-19 in the city of Honghu in Hubei, China. Methods: The HHS was designed for the collection, integration, standardization, and analysis of COVID-19-related data from multiple sources, which includes a case reporting system, diagnostic labs, electronic medical records, and social media on mobile devices. Results: HHS supports four main features: syndromic surveillance on mobile devices, policy-making decision support, clinical decision support and prioritization of resources, and follow-up of discharged patients. The syndromic surveillance component in HHS covered over 95% of the population of over 900,000 people and provided near real time evidence for the control of epidemic emergencies. The clinical decision support component in HHS was also provided to improve patient care and prioritize the limited medical resources. However, the statistical methods still require further evaluations to confirm clinical effectiveness and appropriateness of disposition assigned in this study, which warrants further investigation. Conclusions: The facilitating factors and challenges are discussed to provide useful insights to other cities to build suitable solutions based on cloud technologies. The HHS for COVID-19 was shown to be feasible and effective in this real-world field study, and has the potential to be migrated.

1 July 2021 in Lung Cancer
Verified
Journal Article
Open access
HLHaike Lei
Haike Lei
YYYue Yang
Yue Yang
WZWei Zhou
Wei Zhou
MZMengyang Zhang
Mengyang Zhang
YSYang Shen
Yang Shen
YWYongzhong Wu
Yongzhong Wu
Given that the coronavirus disease 2019 (COVID-19) mainly spreads through the respiratory system and is associated with severe pulmonary complications, lung cancer patients may have worse outcomes than those with other tumors. There is no confirmed evidence about the mortality comparison between COVID-19 patients with lung cancer and other tumors. We performed a systematic review and pooled analysis to provide precise estimates of the mortality rate of COVID-19 patients with lung cancer and other tumors. Our study systemically included and reviewed 13 studies on the characteristics of COVID-19 patients with lung cancer published up to November 1, 2020. The primary endpoint was all-cause mortality. We also compared the all-cause mortality rates in China and other regions as a secondary endpoint. The mortality rate was assessed with a fixed-effects model, which was used to derive the pooled mortality and 95 % confidence interval (CI). Thirteen studies from different countries, involving 1,229 patients with both COVID-19 and cancer, were selected for the pooled analysis. A total of 343 deaths were recorded in this population: 86 for lung cancers and 257 for other tumors. The mortality rate varies from 18 % to 60 % for patients with lung cancer and COVID-19 and 10%–41% for other tumor patients with COVID-19. The overall meta-analysis did not show a significant mortality difference for the lung cancer and other tumor subgroups (OR = 1.47, 95 %CI = 0.98–2.20, p = 0.06, I2 = 23 %). Nevertheless, in regions other than China, the pooled mortality of lung cancer patients with COVID-19 was 42 %, which was significantly higher than that of other tumors (24 %) (OR = 2.73, 95 % CI = 1.54–4.86, p = 0.0006, I2 = 16 %). Appropriate and aggressive preventive measures should be implemented to reduce the risk of COVID-19 in patients with cancer and optimally manage those who contract the infection.

29 March 2020 in JMIR Preprints
Verified
Preprint
Open access
MGMengchun Gong
Mengchun Gong
LLLi Liu
Li Liu
XSXin Sun
Xin Sun
YYYue Yang
Yue Yang
SWShuang Wang
Shuang Wang
HZHong Zhu
Hong Zhu
BACKGROUND Coronavirus disease (COVID-19) has been an unprecedented challenge to the global health care system. Tools that can improve the focus of surveillance efforts and clinical decision support are of paramount importance. OBJECTIVE The aim of this study was to illustrate how new medical informatics technologies may enable effective control of the pandemic through the development and successful 72-hour deployment of the Honghu Hybrid System (HHS) for COVID-19 in the city of Honghu in Hubei, China. METHODS The HHS was designed for the collection, integration, standardization, and analysis of COVID-19-related data from multiple sources, which includes a case reporting system, diagnostic labs, electronic medical records, and social media on mobile devices. RESULTS HHS supports four main features: syndromic surveillance on mobile devices, policy-making decision support, clinical decision support and prioritization of resources, and follow-up of discharged patients. The syndromic surveillance component in HHS covered over 95% of the population of over 900,000 people and provided near real time evidence for the control of epidemic emergencies. The clinical decision support component in HHS was also provided to improve patient care and prioritize the limited medical resources. However, the statistical methods still require further evaluations to confirm clinical effectiveness and appropriateness of disposition assigned in this study, which warrants further investigation. CONCLUSIONS The facilitating factors and challenges are discussed to provide useful insights to other cities to build suitable solutions based on cloud technologies. The HHS for COVID-19 was shown to be feasible and effective in this real-world field study, and has the potential to be migrated.

18 May 2026 in Journal of Diabetes Science and Technology
Verified
Journal Article
Closed access
LZLin Zhao
Lin Zhao
HYHongying Ye
Hongying Ye
BFBo Feng
Bo Feng
YYYue Yang
Yue Yang
YLYang Li
Yang Li
XLXiaoying Li
Xiaoying Li
Background: Performance of the uCGM 100 continuous glucose monitoring (CGM) system, featuring a 15.5-day, real-time, and factory-calibrated glucose sensor, is evaluated against venous plasma reference for adult participants (≥18 years) in a multicenter, prospective clinical study. Methods: A total number of 60 participants were enrolled at three clinical sites in China, and each participant wore sensors on the back of each upper arm for 15.5 days. Three in-clinic visits, lasting eight hours during each visit, were conducted by each participant to perform multiple venous plasma glucose measurements using Biosen C-Line GP+ (EKF Diagnostics) Glucose/Lactate Measuring System. Venous plasma blood glucose sample tests covered the start, middle, and end wear of the sensor (day 1, days 3-5, days 7-9, days 11-13, or the last 24 hours). Analytic performance included accuracy such as ±20% or ±20 mg/dL (%20/20) agreement rate with reference values, and mean absolute relative difference (MARD) between CGM and reference values. Results: A total of 11 576 matched data pairs (120 sensors) were analyzed. The overall MARD and %20/20 agreement rate for the CGM system was 7.6% and 95.5%, respectively, compared with venous blood reference. The %20/20 agreement remained consistently above 93% across wear days and glucose ranges. No serious adverse events were recorded. Usability survey showed 99.8% positive feedback, demonstrating good usability. Conclusions: The novel CGM system was proven to provide accurate and reliable glucose readings in adults with diabetes.